New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
09:21 EDTAZN, TEVA, MNTA, CBEY, ATHN, ACTG, AMD, ABX, NEM, NUS, RNA, SRPT, PFE, MUOn The Fly: Pre-Market Movers
HIGHER: Sarepta (SRPT), up 54% after announcing plans to to submit NDA for Eteplirsen by year end 2014. Shares of Prosnesa (RNA), another drugmaker working on a competing DMD drug, are up more than 12%... AstraZeneca (AZN), up 6% after the Sunday Times says that Pfizer (PFE) is considering a takeover bid for the company. Pfizer is up 1.2% following the report... Newmont Mining (NEM), up 8% after WSJ says the company and Barrick Gold (ABX) could resume merger talks as soon as today... Cbeyond (CBEY), up 39% after agreeing to be acquired for about $323M by Birch Communications... Momenta Pharma (MNTA), up 10.5% after the Supreme Court rejected Teva's (TEVA) bid to delay generic Copaxone... Nu Skin (NUS), up 5% after saying its China division will resume corporate-hosted business meetings... Micron (MU), up 4% after price target raised at Drexel Hamilton... DOWN AFTER EARNINGS: Acacia Research (ACTG), down 6%... athenahealth (ATHN), down 5.6%.
News For AZN;PFE;SRPT;RNA;NUS;NEM;ABX;AMD;ACTG;ATHN;CBEY;MNTA;TEVA;MU From The Last 14 Days
Check below for free stories on AZN;PFE;SRPT;RNA;NUS;NEM;ABX;AMD;ACTG;ATHN;CBEY;MNTA;TEVA;MU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 10, 2014
11:52 EDTSRPTJanney Capital reiterates Sell rating on Sarepta
Subscribe for More Information
11:50 EDTSRPTSarepta story correction issued by Wall Street Journal
The Wall Street Journal reported that its prior story, entitled "Sarepta to Submit Study on Muscular Dystrophy Drug to FDA Later Than Expected," at 9:12 a.m. EDT incorrectly suggested the decision to delay the application was unveiled Thursday. The Journal noted in its correction that the delay was previously reported. Reference Link
11:15 EDTSRPTSarepta shares defended at Stifel
11:09 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
10:54 EDTSRPTSarepta shares defended at Needham
Needham said Sarepta weakness is unjustified and due to a confusing, inaccurate Wall Street Journal article that says the eteplirsen NDA is delayed. THe analyst said Sarepta maintains the NDA will be filed by 2014 year end and reiterates its Buy rating and $52 price target.
10:02 EDTSRPTSarepta tumbles, levels to watch
Subscribe for More Information
08:55 EDTATHNathenahealth volatility increases into Q2 and outlook
Subscribe for More Information
08:34 EDTSRPTSarepta plans to submit long-term eterplirsen results as part of NDA by year-end
Subscribe for More Information
08:32 EDTSRPTSarepta says on track to initiate several new studies of eteplirsen
Subscribe for More Information
08:32 EDTSRPTSarepta reports long-term outcomes from Phase IIb Eteplirsen study
Subscribe for More Information
July 9, 2014
12:46 EDTCBEYCbeyond stockholders approve merger agreement
Subscribe for More Information
11:51 EDTSRPTOptions with increasing implied volatility:
Subscribe for More Information
11:30 EDTMUMicron shares defended at Sterne Agee
Subscribe for More Information
10:36 EDTMUMicron trades lower, levels to watch
The shares were last down over 3% to $32.13 as the stock edges away from its recent 52-week high at $34.50. The 10-day moving average has been broken to the downside, last at $32.88 and now resistance. That break is short-term bearish for price. Next support below current levels is at $31.26, and then at the 30-day moving average last at $30.81.
09:40 EDTMUSamsung raisiing DRAM capacity, says Morgan Stanley
Subscribe for More Information
09:35 EDTMUActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AA FB AMZN TSLA TWTR MU NFLX GG CELG
07:15 EDTTEVATeva, others fined $583.4M by EU regulators, Reuters says
Subscribe for More Information
06:49 EDTTEVAGeneric drug prices have risen significantly, NY Times says
Subscribe for More Information
06:49 EDTPFEPfizer given dismissal of U.S. investor class action before trial, Reuters says
Subscribe for More Information
06:04 EDTACTGAcacia Research enters into settlement and license agreement with Mitac Digital
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use